BRAF and melanoma: Most recently, MITF-dependent BCL2A1 was identified as an oncogene restricted to melanoma versus normal tissues, and the co-treatment of V600EBRAF melanomas with BRAF inhibitors and obatoclax, an inhibitor of BCL2A1, reduced the resistance to BRAF inhibitors in BCL2A1-amplified melanoma cells in vitro and in vivo[55].